Retraction notice to "Population pharmacokinetic and pharmacodynamic analysis of bosutinib" [Drug Metab Pharmacokinet 29 (2014) 441-448]

Poe-Hirr Hsyu; Diane R Mould; Richat Abbas; Michael Amantea

doi:10.1016/j.dmpk.2019.01.003

Retraction notice to "Population pharmacokinetic and pharmacodynamic analysis of bosutinib" [Drug Metab Pharmacokinet 29 (2014) 441-448]

Drug Metab Pharmacokinet. 2019 Apr;34(2):163. doi: 10.1016/j.dmpk.2019.01.003. Epub 2019 Feb 10.

Authors

Poe-Hirr Hsyu¹, Diane R Mould², Richat Abbas³, Michael Amantea¹

Affiliations

¹ Pfizer Inc, La Jolla, CA, USA.
² Projections Research Inc, Phoenixville, PA, USA.
³ Pfizer Inc, Collegeville, PA, USA.

PMID: 30922682
DOI: 10.1016/j.dmpk.2019.01.003

Abstract

This article [1] has been retracted: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy). This article has been retracted at the request of the authors. According to the authors, their recent analyses have revealed that the model presented may lead to inaccurate conclusions, particularly regarding the peripheral volume of distribution and beta half-life of the compound. Since the model is critical to the article and its conclusion, the editor has approved to retract the article.

Publication types

Retraction of Publication